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Geographic Medicine, Tufts University School of Medicine, Boston,and David Acheson
Massachusetts; Department of Medicine, Division of Infectious Disease
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Stools of 68 human immunodeficiency virus (HIV)–infected adults with diarrhea and 60 without
diarrhea were examined for enteroaggregative Escherichia coli (EAggEc) by HeLa cell adherence
assay. EAggEc were present in stools of 30 patients with and 18 without diarrhea (P  .05). CD4
cell counts of patients with EAggEc and diarrhea were significantly lower than those of patients
with EAggEc without diarrhea (P  .02). There was no difference in the mean duration of diarrheal
symptoms or in the number of stools per day between patients with EAggEc and those without.
None of the EAggEc strains were positive by polymerase chain reaction for adherence fimbria, but
11 strains were positive for EAggEc heat-stable toxin EAST/1. Of the EAggEc strains, 51% were
resistant to trimethoprim-sulfamethoxazole and 65% were resistant to ampicillin. EAggEc may be
a pathogen in HIV-infected patients with diarrhea; HIV-infected patients with EAggEc appear to
be more symptomatic when HIV disease is more advanced.
Enteroaggregative Escherichia coli (EAggEc) have been as- ally, some strains have been shown to produce a larger protein
toxin that activates interleukin-8 [16]. Additional strains havesociated with persistent diarrheal disease in children in the
demonstrated the ability to invade HeLa or intestinal cell cul-developing world [1±6]. The mechanisms by which these or-
tures and subvert cellular tyrosine phosphorylation or produceganisms cause diarrheal disease are not well understood. Vari-
a novel cryohemagglutinin [17, 18]. None of the potential viru-ous strains of EAggEc from diverse populations of children
lence traits has been identi®ed in all or even a majority ofwith diarrhea from around the world have demonstrated differ-
EAggEc strains from diverse geographic areas. The preciseent potential virulence traits, which have not been found consis-
clinical relevance of any of these virulence traits remains un-tently among strains from all geographic regions [7±9]. Strains
clear.all appear to aggregate in the HeLa or HEp-2 tissue culture
Equally disturbing is the fact that healthy adult volunteersassay, and this phenotype serves, to date, as the most reliable
who ingest EAggEc strains and are colonized by them do notmeans to identify EAggEc. Organisms have been described to
consistently develop diarrheal disease [19]. This raises the pos-have a pilus adhesin, AAF1, composed of a subunit AggA,
sibility that EAggEc may function as a more opportunisticand AggR, a regulator, which has been shown to be responsible
pathogen in young or immunologically compromised patients.for the aggregative adherence of the organisms [10±13].
That is, EAggEc may cause diarrhea in some immunologicallyEAggEc organisms have also been shown to produce a heat-
normal hosts when the numbers of organisms or some hoststable toxin, EAggEC heat-stable toxin (EAST/1), which ap-
factor favors the organism but more easily can routinely causepears to mediate secretion through cGMP [14, 15]. Addition-
diarrhea in persons who are somewhat compromised in terms
of intestinal function or nutritional status or who manifest some
other immunologic defect. As these organisms cannot be identi-
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Patients who are infected with HIV frequently develop per-
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q 1998 by the Infectious Diseases Society of America. All rights reserved.
0022±1899/98/7801±0023$02.00 matic [26, 27]. We elected to examine a group of HIV-infected
/ 9d4a$$jy19 05-27-98 00:22:21 jinfa UC: J Infect
186 Wanke et al. JID 1998;178 (July)
patients with and without diarrheal disease to determine
whether EAggEc were present in those with unexplained diar-
rhea. We also surveyed E. coli from stools of persons who
were not known to be infected with HIV to estimate the baseline
occurrence of EAggEc in an adult population with and without
diarrhea in Boston. As there has been no single factor that has
consistently characterized these organisms, we characterized
the EAggEc strains we recovered from the HIV-infected pa-
tients as completely as possible.
Methods
Population. Urban, hospital-based HIV clinics in Boston and
Zurich were used to recruit the diarrheal disease patients and nondi-
arrheal control patients for the study.
HIV-infected adults who were followed at either of these two
Figure 1. Primers used for detection of recognized adherence ®m-clinics who had complained of diarrheal symptoms on at least two
bria and EAggEc heat-stable toxin (EAST/1).visits to their primary care physician were screened for EAggEc as
well as routine pathogens. Randomly selected, unmatched control
patients infected with HIV, followed at the same clinic, who did
not have diarrheal disease or any change in bowel habits, were in sterile PBS on the second day of the assay. The tissue culture
cells were washed and refed with 0.5 mL of fresh medium, withoutrecruited as HIV-infected controls. Patient data were obtained and/
or veri®ed by interview and by chart review. The data collected fetal calf serum or antibiotics. Twenty microliters of the overnight
culture of bacterial suspension was added to each well of cells,included a description of and the duration of diarrheal symptoms,
medications, gastrointestinal evaluation, other medical history, and incubated for 2 h, and then washed ®ve times with sterile PBS,
®xed with 100% methanol, and stained with Giemsa. Positive andlaboratory data including CD4 cell count. Exposure data including
employment, travel history, pets, and source of drinking water negative controls were included in each assay. All assays were
read blinded by two investigators.were also collected when possible.
In addition, stools from adult patients who were not known to Additional EAggEc characterization by bacterial endocytosis.
All E. coli strains were tested for the ability to invade eukaryoticbe infected with HIV but who presented with diarrhea and had
submitted a stool culture to one of the microbiology laboratories cells in the gentamicin protection assay [17]. For this assay, HeLa
cells were seeded into 24-well plates for 18 h. Each well was(Boston) were also screened for the presence of EAggEc. Patient
data for this group, including the level of suspicion of potential inoculated with 20 mL of an E. coli strain prepared as described
above and incubated for 2 h. Cells were washed with sterile PBSHIV exposure, were obtained by interviewing the physician who
obtained the stool for culture. Stools from healthy adult volunteers and refed with media with 50 mg/mL gentamicin for an additional
2 h. HeLa cells were lysed with 0.125% sodium deoxycholate.without diarrhea and either with no recognized risk factor for
acquisition of HIV or known to be HIV-negative were also Serial dilutions of this lysate were plated on Luria agar to deter-
mine the number of viable intracellular bacteria. Isolates werescreened for the presence of EAggEc. EAggEc strains identi®ed
from either of these groups of patients were not characterized considered positive if 5% of the original inoculum was internal-
ized, as previously de®ned [17]. Positive and negative controlsfurther in this study.
Routine stool culture and examination. Stool specimens were were included in each assay.
Verotoxin production. Vero cells (ATCC) were seeded in 24-cultured for Salmonella, Shigella, Campylobacter, and Yersinia
species and were tested for Clostridium dif®cile toxin. Stool speci- well plates and incubated for 18 h. Cells were washed and refed
with MEM and 5% fetal calf serum. The E. coli strains weremens were examined for ova and parasites, cryptosporidia, mi-
crosporidia, and acid-fast bacilli by use of a ¯uorescent antibody grown in Luria-Bertani broth overnight and centrifuged, and the
supernatant was ®ltered through a 0.45-mm ®lter; 0.5 mL of thisstain for cryptosporidia and the modi®ed trichrome and chitin stain
for microsporidia. ®ltered bacterial supernatant was added to each well. Cells were
incubated at 377C and examined for visible cell rounding at 24EAggEc assay. Two to 5 colonies of E. coli were selected for
each patient and control and stocked at 0707C in Luria broth and and 48 h and for cell death by trypan blue exclusion at 48 h.
Positive and negative controls were included in each assay.glycerol. E. coli were assayed in the HeLa cell adherence assay,
as previously described [5, 28]. Brie¯y, HeLa cells (American Antibiotic sensitivity. Susceptibility testing was done by the
disk diffusion method in accordance with National Committee forType Culture Collection, Rockville, MD) that had been grown to
con¯uence in MEM (Gibco-BRL, Gaithersburg, MD) with 10% Clinical Laboratory Standards guidelines.
Polymerase chain reaction (PCR). E. coli strains were assayedfetal calf serum but without antibiotics were plated in 8-well Lab-
tek Slides (Dynatek, Naperville, IL) in fresh medium and incubated for the presence of the recognized aggregative adherence ®mbria
AAF1, as well as the genes for AggR, the regulator, and AggA,overnight at 377C with 10% CO2. Each E. coli strain was also
grown overnight in 5 mL of Luria broth, washed, and resuspended a subunit, and for the presence of EAST/1 genes by PCR. The
/ 9d4a$$jy19 05-27-98 00:22:21 jinfa UC: J Infect
187JID 1998;177 (July) Enteroaggregative E. coli and HIV Diarrhea
primers used are shown in ®gure 1. The AAF1 primers were gener- CD4 cell count for patients with diarrhea was 128 { 187 cells/
ated from pCVD432. Forty cycles of PCR were done directly from mm3; the median was 50. The mean CD4 cell count for patients
bacterial colonies grown on Luria-Bertani agar plates, and strain without diarrhea was 222 { 193 cells/mm3; the median was
17-2 was used as a positive control in each PCR run [29]. In our 190. The CD4 cell count of patients with diarrhea was signi®-
hands, the adherence probe for aggregative adherence correlates cantly lower than that of patients without diarrhea (P  .008).
100% with this PCR methodology (93 strains tested using the
There were no signi®cant differences between the patients from
primers as described; unpublished data).
Boston and Zurich in duration of diarrhea or CD4 cell counts.Statistical analysis. Variables were analyzed by logistic re-
Thirty (44%) of those with diarrhea had phenotypic evidencegression modeling. CD4 cell counts were analyzed as a continuous
of EAggEc organisms in their stool cultures. Eighteen of theseand dichotomous variable. Odds ratios (ORs) with 95% con®dence
patients were from Zurich (55%) and 12 were from Bostonintervals (CIs) were used as measures of association. Continuous
variables were analyzed by Student's t test. (34%). These patients and the patients with diarrhea who did
not have EAggEc in stool are described in table 2. The patients
with EAggEc and diarrhea complained of diarrheal symptoms
Results
for a mean of 12.9 { 12.1 weeks and had a mean of 5.1 {
2.5 bowel movements per day. The patients with diarrhea andSurveillance of adults without HIV infection. The stools of
68 adult patients with diarrhea or abdominal complaints that EAggEc in stool for whom serial weights were available had
lost a mean of 7.3 kg (range, 0±22). HIV-infected patientswere submitted to the microbiology laboratory of the Beth
Israel Deaconess Medical Center were examined for the pres- who had diarrhea but did not have EAggEc organisms in the
stool had diarrheal symptoms for a mean of 9.3 { 9.9 weeks;ence of EAggEc. These patients were not known to be HIV-
positive and were not at high risk for HIV infection by inter- this difference was not signi®cant. These patients with diarrhea
but without EAggEc in stool had a mean of 4.1 { 2.7 bowelview with patient physicians and/or review of patient records.
Many of these patients did have other comorbid illnesses, such movements per day (P  .08 vs. patients with EAggEc) and
had lost a mean of 3.9 kg (range, 0±13.6) (P  .06 vs. weightas in¯ammatory bowel disease, diabetes mellitus, or irritable
bowel syndrome, or had a history of travel to the developing loss in HIV-infected patients with EAggEc and diarrhea). CD4
cell counts of the patients with diarrhea who had EAggEc inworld. Nineteen (28%) of these patients had phenotypic evi-
dence of EAggEc in their stool. Sixteen of these had a comorbid stool were not different from CD4 cell counts of patients with
diarrhea but without EAggEc in stool. The mean CD4 cellillness. An additional 52 adults without diarrhea who were not
known to have HIV infection or to be at high risk of HIV count of patients with EAggEc and diarrhea was 94 { 105
cells/mm3 (median, 50), and the mean CD4 cell count of theinfection and who had no signi®cant or chronic medical ill-
nesses were recruited to submit stools for EAggEc assay. Seven patients without EAggEc was 157 { 233 cells/mm3 (median,
50). There were no signi®cant differences between the patients(13%) of these adults had EAggEc in their stools. EAggEc
were present signi®cantly more often in the stools of the adults from Zurich and Boston in duration of diarrhea, numbers of
stools, or amount of weight loss. Stool cultures for routinewith diarrhea than of those without diarrhea (P  .05).
Surveillance of adults with HIV infection. Of the 134 HIV- enteric pathogens were negative for all of the patients enrolled
in the study. Some patients had been sent for upper or lowerinfected patients enrolled, 117 were male and 17 female. Sixty-
three patients were enrolled from Zurich (33 with diarrhea and endoscopy by their primary care physicians. Results of these
investigations are shown in table 2.30 without diarrhea) and 71 were enrolled from Boston (35
with diarrhea and 36 without diarrhea). Demographic data are Organisms phenotypically consistent with EAggEc were also
present in the stools of 18 (27%) of the 66 HIV-infected patientsshown in table 1. Patient ages ranged from 22 to 66 years
(mean, 39). Seventy-two percent of the male patients had sex without diarrhea; 13 of these were from Zurich and 5 were from
Boston. EAggEc were present signi®cantly more often in stoolswith men as the risk factor for HIV infection. Seventy-six
patients (57%) were taking antiretroviral therapy; 32% of those of patients with diarrhea than in stools of patients without diar-
rhea in the population as a whole (P .05). When the populationwere taking zidovudine. Forty-four patients (33%) were taking
trimethoprim-sulfamethoxazole as prophylaxis for Pneumo- was divided by location, EAggEc were present signi®cantly
more often in patients with diarrhea than in patients withoutcystis carinii pneumonia. CD4 lymphocyte counts for the en-
rolled patients ranged from 0 to 1080 cells/mm3 (mean { SD, diarrhea from Boston, but the difference did not reach signi®-
cance for the population from Zurich. Overall, there was a trend173 { 203). The median CD4 cell count for the entire group
was 100 cells/mm3. toward an association between the presence of EAggEc and both
acute and persistent diarrhea (OR, 2.7; 95% CI, 0.73±10; vs.Of these 134 HIV-infected patients, 68 had diarrhea and 66
were controls, with no complaints of diarrhea. Fifty-three of OR, 1.3; 95% CI, 0.6±2.7). The nondiarrheal control patients
who had EAggEc identi®ed in stool had a mean CD4 cell countthe patients with diarrhea (78%) had diarrhea that had lasted
28 days (persistent diarrhea) and 15 (22%) had diarrheal that was signi®cantly higher (188 { 190 cells/mm3; median,
170) than that of patients with diarrhea who had EAggEc insymptoms for 28 days (acute diarrhea). The overall range of
diarrheal symptoms was 1±52 weeks (mean, 11). The mean stool or patients with diarrhea who did not have EAggEc in
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Table 1. Baseline characteristics of HIV-infected adults with and without diarrhea.
Boston Zurich Overall
Characteristic (n  71) (n  63) (n  134)
Male 67 (94) 50 (79) 117 (87)
Female 4 (6) 13 (21) 17 (13)
Age, years, mean { SD 39 { 8 38.1 { 9 39 (range, 22±66)
HIV risk factor*
Homosexual 59 37 96 (72)
Hemophilia 1 1 2 (1)
Intravenous drug use 8 14 22 (16)
Heterosexual 4 5 9 (7)
Unknown 0 1 1
Antiretroviral therapy 44 32 76 (57)
Trimethoprim-sulfamethoxazole for PCP prophylaxis 24 20 44 (33)
Median CD4 cell count/mm3 80 130 100
Mean CD4 cell count/mm3 { SD 172 { 220 176 { 160 173 { 203
NOTE. Data are no. of patients or no. (%) unless indicated. PCP, Pneumocystis carinii pneumonia.
* More than 1 risk factor may have been reported for each person.
stool (P  .02 for each). When strati®ed by the presence or or aerosolized pentamidine as P. carinii pneumonia prophylaxis
nor in the presence of other epidemiologic clues for the poten-absence of diarrhea, the presence of EAggEc in stool was associ-
ated with a lower CD4 cell count, even when controlled for tial acquisition of EAggEc organisms. For the patients for
whom data were available, there was no association of EAggEczidovudine and trimethoprim-sulfamethoxazole usage (P .03).
There were no differences in the numbers of patients in any with employment, presence of pets, travel history, exposure to
children, or source of drinking water. The Boston and Zurichgroup for the use of trimethoprim-sulfamethoxazole, dapsone,
groups did not differ in respect to these exposures (data not
shown).
Twenty-one patients with diarrhea had undergone furtherTable 2. Characteristics of HIV-infected patients with diarrhea.
gastrointestinal evaluation; 12 of these had EAggEc in stool
Diarrhea with Diarrhea and 9 did not. Of the 12 with diarrhea and EAggEc, 1 patient
EAggEc without EAggEc was also found to have microsporidia, and 1 had cytomegalovi-
Characteristic (n  30)* (n  38)² P
rus colitis. One patient with EAggEc in stool also had lesions
suggestive of bacterial enteritis in the distal ileum. For the 9Mean duration of symptoms,
weeks 12.9 { 12.1 9.3 { 9.9 NS patients with diarrhea who did not have EAggEc organisms in
Mean no. of stools/day 5.1 { 2.5 4.1 { 2.7 .08 the stool, 1 patient had microsporidia, 1 had cytomegalovirus
Mean decrease in weight, kg 7.3 { 6.8 3.9 { 4.6 .06 colitis, and the remainder had unrevealing gastrointestinal eval-
Mean CD4 cells/mm3 94 { 105 157 { 233 NS
uations.Boston 85 145
Characterization of EAggEc organisms. EAggEc organ-Zurich 104 163
Median CD4 cells/mm3 50 50 isms in this study were identi®ed by phenotype, so all strains
Boston 45 42 considered to be EAggEc were phenotypically positive, by
Zurich 53 80 de®nition, in the adherence assay. EAggEc strains from HIV-
Other GI evaluation,³
positive patients were assayed by PCR for the presence ofno. (%) 12 (40) 9 (24) NS
AAF1, AggR, AggA, and EAST/1 genes. Of 59 strains tested,Other GI pathogens
identi®ed Microsporidia: 1 Microsporidia: 1 11 strains were positive for EAST/1; no strain was positive for
CMV colitis: 1 MCV colitis: 1 AAF1, AggA, or AggR. None of the strains had evidence of
None: 10 None: 7 cytotoxin production in the Vero cell assay. Four patients had
Mean age, years 41.2 { 10.7 37.5 { 6.7 NS
EAggEc strains that were positive for invasion in the HeLa
cell gentamicin protection assay. The antibiotic sensitivities ofNOTE. Means are given { SDs. NS, not signi®cant.
* 18 patients with diarrhea and EAggEc were from Zurich and 13 were from the EAggEc organisms are shown in table 3.
Boston.
² 15 patients with diarrhea without EAggEc were from Zurich and 23 were
Discussionfrom Boston.
³ Other gastrointestinal (GI) evaluation: these patients had been sent by their
EAggEc organisms are traditionally associated with persis-primary physician for upper or lower endoscopy as part of their evaluation for
diarrheal disease. tent diarrheal disease in children in the developing world. Our
/ 9d4a$$jy19 05-27-98 00:22:21 jinfa UC: J Infect
189JID 1998;177 (July) Enteroaggregative E. coli and HIV Diarrhea
Table 3. Antibiotic sensitivities of EAggEc strains from HIV-in- The antibiotic sensitivity data in our study suggest that treat-
fected adults (n  49). ment studies will need to take the resistant nature of EAggEc
into account, as a high proportion of organisms are resistant to
Antibiotic Susceptible Intermediate Resistant
antibiotics such as ampicillin and trimethoprim-sulfamethoxa-
zole. A previous study has reported that EAggEc organisms areTrimethoprim-sulfamethoxazole 24 (49) 2 (4) 23 (47)
Ampicillin 17 (35) 4 (8) 28 (57) fairly antibiotic-resistant and suggested that resistance may be
Chloramphenicol 31 (63) 3 (6) 15 (31) linked to virulence [30]. In our population, such resistance may
Gentamicin 44 (90) 1 (2) 4 (8) not be an intrinsic feature of the EAggEc organisms but may
Cipro¯oxacin 47 (96) 1 (2) 1 (2)
have occurred in the organisms in this study because of the high
NOTE. Data are no. (%). rate of antibiotic exposure in patients infected with HIV. Such
resistance may assist in selecting for the predominance of these
organisms in stools of patients infected with HIV.
Further epidemiologic data are needed to clarify the role ofstudy did demonstrate an association between EAggEc organ-
isms in stool and diarrhea or abdominal complaints in a series of EAggEc in diarrheal disease and weight loss in patients with
HIV throughout the world. If treatment studies could demon-adults without HIV. Our study also demonstrated that EAggEc
occurs in stools of patients infected with HIV with diarrhea strate that eradicating these organisms does alleviate the diar-
rheal symptoms or improve the nutritional status in HIV-in-more frequently than in stools of HIV-infected adults without
diarrhea. The rates at which EAggEc were identi®ed from diar- fected patients who carry EAggEc, this could result in the
development of a relatively simple intervention that could alle-rheal and nondiarrheal patients infected with HIV in our study
are consistent with those in studies of persistent diarrheal ill- viate signi®cant morbidity associated with HIV infection. Ulti-
mately, the precise virulence factors in the EAggEc organismsnesses in children in the developing world. There appears to
be an association between EAggEc in patients symptomatic need to be understood so that more accessible diagnostic meth-
ods for these organisms can be developed.with diarrhea and lower CD4 cell counts as a measure of more
advanced HIV illness in these patients. We believe that EAg-
gEc may well represent an opportunistic pathogen in the HIV-
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